Statins and their potential targets in multiple sclerosis therapy

Bibliography

• ANDERSON DW, ELLENBERG JH, LEVENTHAL CM, REINGOLD Sc, RODRIGUEZ M, SILBERBERG DH: Revised estimate of the prevalence of multiple sclerosis in the United States. Ann. Neurol (1992) 31:333–336.
   PubMed Web of Science ®Google Scholar
• STEINMAN L: Multiple sclerosis: a two-stage disease. Nat. Immunol (2001) 2:762–764.
   PubMed Web of Science ®Google Scholar
• LUBLIN FD, REINGOLD SC: Guidelines for clinical trials of new therapeutic agents in multiple sclerosis: relations between study investigators, advisors, and sponsors. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology(1997) 48:572–574.
   Google Scholar
• ARNASON BG: Relevance of experimental allergic encephalomyelitis to multiple sclerosis. Neurol Clin. (1983) 1:765–782.
   PubMedGoogle Scholar
• RAINE CS: Biology of disease. Analysis of autoimmune demyelination: its impact upon multiple sclerosis. Lab. Invest. (1984) 50:608–635.
   Google Scholar
• MARTIN R, MCFARLAND HF, MCFARLIN DE: Immunological aspects of demyelinating diseases. Anna. Rev Iinmunol. (1992) 10:153–187.
   PubMed Web of Science ®Google Scholar
• WHITACRE CC: Sex differences in autoimmune disease. Nat. Immunol (2001) 2:777–780.
   PubMed Web of Science ®Google Scholar
• MARTYN CN: The epidemiology of multiple sclerosis. In: McAlpine 's Multiple Sclerosis WB Matthews (Ed.), Churchhill Livingstone, New York (1991).
   Google Scholar
• SADOVNICK AD, EBERS GC: Epidemiology of multiple sclerosis: a critical overview. Can. J. Near& Sci. (1993) 20:17–29.
   PubMed Web of Science ®Google Scholar
• HAINES JL, TER MINASSIAN M, BAZYK A et al.: A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group. Nat. Genet. (1996) 13:469–471.
   PubMed Web of Science ®Google Scholar
• SAWCER S, JONES HB, FEAKES R et al: A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat. Genet. (1996) 13:464–468.
   PubMed Web of Science ®Google Scholar
• BARCELLOS LF, OKSENBERG JR, BEGOVICH AB et al.: HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am. J. Hum. Genet. (2003) 72:710–716.
   PubMed Web of Science ®Google Scholar
• HAINES JL, BRADFORD Y, GARCIA MEet al.: Multiple susceptibility loci for multiple sclerosis. Hum. MoL Genet. (2002) 11:2251–2256.
   Google Scholar
• SAWCER S, MARANIAN M, SETAKIS E et al: A whole genome screen for linkage disequilibrium in multiple sclerosis confirms disease associations with regions previously linked to susceptibility. Brain (2002) 125:1337–1347.
   PubMed Web of Science ®Google Scholar
• CORSINI A, BELLOSTA S, BAETTA R, FUMAGALLI R, PAOLETTI R, BERNINI F: New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Then (1999) 84:413–428.
   PubMed Web of Science ®Google Scholar
• LAROSA JC, HE J, VUPPUTURI S: Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA (1999) 282:2340–2346.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344:1383–1389.
   PubMed Web of Science ®Google Scholar
• JUKEMA JW, BRUSCHKE AV, VAN BOVEN AJ et al.: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation (1995) 91:2528–2540.
   Google Scholar
• SHEPHERD J, COBBE SM, FORD let al.:Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl. J. Med. (1995) 333:1301–1307.
   Google Scholar
• SACKS FM, PFEFFER MA, MOYE LA et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. (1996) 335:1001–1009.
   Google Scholar
• HERD JA, BALLANTYNE CM, FARMER JA et al.: Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS1). Am. Cardiol (1997) 80:278–286.
   PubMed Web of Science ®Google Scholar
• DOWNS JR, CLEARFIELD M, WEIS S et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. "AMA (1998) 279:1615–1622.
   Google Scholar
• NO AUTHORS LISTED: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl. I Med. (1998) 339:1349–1357.
   Google Scholar
• RIEGGER G, ABLETSHAUSER C, LUDWIG M et al.: The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherosclerosis (1999) 144:263–270.
   PubMed Web of Science ®Google Scholar
• PITT B, WATERS D, BROWN WV et al: Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl. J. Med. (1999) 341:70–76.
   PubMed Web of Science ®Google Scholar
• ISTVAN ES, DEISENHOFER J: Structural mechanism for statin inhibition of HMG-CoA reductase. Science (2001) 292:1160–1164.
   PubMed Web of Science ®Google Scholar
• GINSBERG HN: Effects of statins on triglyceride metabolism. Am. J. Cardiol (1998) 81:B32–B35.
   Google Scholar
• DAIN JG, FU E, GORSKI J, NICOLETTI J, SCALLEN TJ: Biotransformation of fluvastatin sodium in humans. Drug Metab. Dispos. (1993) 21:567–572.
   PubMed Web of Science ®Google Scholar
• CHRISTIANS U, JACOBSEN W, FLOREN LC: Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol Ther. (1998) 80:1–34.
   Google Scholar
• BLACK DM, BAKKER-ARKEMA RG, NAWROCKI JW: An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor. Arch. Intern. Med. (1998) 158:577–584.
   PubMed Web of Science ®Google Scholar
• DAVIDSON MH: Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust. Drugs (2001) 61:197–206.
   PubMed Web of Science ®Google Scholar
• CHARIOT P, ABADIA R, AGNUS D, DANAN C, CHARPENTIER C, GHERARDI RK: Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am. J. Med. (1993) 94:109–110.
   PubMed Web of Science ®Google Scholar
• HUNG YT, YEUNG VT: Hypothyroidism presenting as hypercholesterolaemia and simvastatin-induced myositis. Hong Kong Med. J. (2000) 6:423–424.
   PubMedGoogle Scholar
• HODEL C: Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol Lett. (2002) 128:159–168.
   PubMed Web of Science ®Google Scholar
• STAFFA JA, CHANG J, GREEN L: Cerivastatin and reports of fatal rhabdomyolysis. N Engl. J. Med. (2002) 346:539–540.
   PubMed Web of Science ®Google Scholar
• GAIST D, GARCIA RODRIGUEZ LA, HUERTA C, HALLAS J, SINDRUP SH: Are users of lipid-lowering drugs at increased risk of peripheral neuropathy? Eur. I Clin. Pharmacol (2001) 56:931–933.
   Google Scholar
• GAIST D, JEPPESEN U, ANDERSEN M, GARCIA RODRIGUEZ LA, HALLAS J, SINDRUP SH: Statins and risk of polyneuropathy: a case-control study. Neurology (2002) 58:1333–1337.
   PubMed Web of Science ®Google Scholar
• LIAO JK: Isoprenoids as mediators of the biological effects of statins. Clin. Invest. (2002) 110:285–288.
   Google Scholar
• GLOMSET JA, GELB MH, FARNSWORTH CC: Prenyl proteins in eukaryotic cells: a new type of membrane anchor. Trends Biochem. Sci. (1990) 15:139–142.
   PubMed Web of Science ®Google Scholar
• MALTESE WA: Posttranslational modification of proteins by isoprenoids in mammalian cells. FASEB J. (1990) 4:3319–3328.
   PubMed Web of Science ®Google Scholar
• VAN AELST L, D'SOUZA-SCHOREY C: Rho GTPases and signaling networks. Genes Dev. (1997) 11:2295–2322.
   PubMed Web of Science ®Google Scholar
• TOLEDANO JE, PARTRIDGE NC: Statins: not just for cholesterol? Trends Endoctinol Metab. (2000) 11:255–256.
   Google Scholar
• GREENWOOD J, WALTERS CE, PRYCE G et al: Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J. (2003) 17:905–907.
   PubMed Web of Science ®Google Scholar
• BELLOSTA S, FERRI N, BERNINI F, PAOLETTI R, CORSINI A: Non-lipid-related effects of statins. Ann. Med. (2000) 32:164–176.
   PubMed Web of Science ®Google Scholar
• WEITZ-SCHMIDT G,WELZENBACH K, BRINKMANN V et al.: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. (2001) 7:687–692.
   Google Scholar
• KOBASHIGAWA JA, KATZNELSON S,LAKS H et al.: Effect of pravastatin on outcomes after cardiac transplantation. N. Engl. J. Med. (1995) 333:621–627.
   Google Scholar
• WEITZ-SCHMIDT G: Statins as anti-inflammatory agents. Trends Pharmacol Sci. (2002) 23:482–486.
   PubMed Web of Science ®Google Scholar
• STUVE O, YOUSSEF S, STEINMAN L, ZAMVIL SS: Statins as potential therapeutic agents in neuroinflammatory disorders. Curr. Opin. Nemo]. (2003) 16:393–401.
   PubMed Web of Science ®Google Scholar
• PAHAN K, SHEIKH FG, NAMBOODIRI AM, SINGH I: Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. Clin. Invest (1997) 100:2671–2679.
   Google Scholar
• STANISLAUS R, PAHAN K, SINGH AK, SINGH I: Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. Neurosci. Lett. (1999) 269:71–74.
   PubMed Web of Science ®Google Scholar
• •The first report of the positive effects of a statin on EAE.
   Google Scholar
• STANISLAUS R, SINGH AK, SINGH I:Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis. J. Neurosci. Res. (2001) 66:155–162.
   PubMed Web of Science ®Google Scholar
• YOUSSEF S, STUVE O, PATARROYO JCet al.: The HMG-CoA reductase inhibitor, atorvastatin, promotes a TH2 bias and reverses paralysis in central nervous system autoimmune disease. Nature (2002) 420:78–84.
   Google Scholar
• •This study confirmed the beneficial clinical effects of statins on EAE. In addition, it was demonstrated that atorvastatin induces a TH2 phenotype, and downregulates MHC II and costirnulatory molecules on APCs.
   Google Scholar
• AKTAS O, WAICZIES S, SMORODCHENKO A et al: Treatment of relapsing paralysis in experimental encephalomyelitis by targeting TH1 cells through atorvastatin. J. Exp. Med. (2003) 197:725–733.
   PubMed Web of Science ®Google Scholar
• •The authors of this study show that atorvastatin inhibited antigen-specific and nonspecific proliferative responses. Inhibition of proliferation was linked to a negative regulation on cell cycle progression.
   Google Scholar
• ZAMVIL SS, STEINMAN L: The T lymphocyte in experimental allergic encephalomyelitis. Annu. Rev Immunol (1990) 8:579–621.
   PubMed Web of Science ®Google Scholar
• WEKERLE H, LININGTON C, LASSMANN H, MEYERMANN R: Cellular immune reactivity within the CNS. Trends Neurosci. (1986) 9:271–277.
   Web of Science ®Google Scholar
• HICKEY WF, HSU BL, KIMURA H: T-lymphocyte entry into the central nervous system. J. NeuroscL Res. (1991) 28:254–260.
   PubMed Web of Science ®Google Scholar
• HICKEY WF: Migration of hematogenouscells through the blood-brain barrier and the initiation of CNS inflammation. Brain PathoL (1991) 1:97–105.
   PubMed Web of Science ®Google Scholar
• MACH B, STEIMLE V, MARTINEZHSORIA E, REITH W: Regulation of MHC Class II genes: lessons from a disease. Anna. Rev Itninunol. (1996) 14:301–331.
   PubMed Web of Science ®Google Scholar
• CHANG CH, FLAVELL RA: Class II transactivator regulates the expression of multiple genes involved in antigen presentation. J. Exp. Med. (1995) 181:765–767.
   PubMed Web of Science ®Google Scholar
• MUHLETHALER-MOTTET A, OTTEN LA, STEIMLE V, MACH B: Expression of MHC Class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J. (1997) 16:2851–2860.
   PubMed Web of Science ®Google Scholar
• PISKURICH JF, WANG Y, LINHOFF MW, WHITE LC, TING JP: Identification of distinct regions of 5 flanking DNA that mediate constitutive, IFN-y, STAT1, and TGF-P-regulated expression of the class II transactivator gene. Immunol (1998) 160:233–240.
   Google Scholar
• SOOS JM, MORROW J, ASHLEY TA, SZENTE BE, BIKOFF EK, ZAMVIL SS: Astrocytes express elements of the Class II endocytic pathway and process central nervous system autoantigen for presentation to encephalitogenic T cells. ImmunoL (1998) 161:5959–5966.
   Google Scholar
• DONG Y, ROHN WM, BENVENISTE EN: IFN-y regulation of the Type IV Class II transactivator promoter in astrocytes. Immunol (1999) 162:4731–4739.
   Google Scholar
• O'KEEFE GM, NGUYEN VT, BENVENISTE EN: Class II transactivator and Class II MHC gene expression in microglia: modulation by the cytokines TGF-I3, IL-4, IL-13 and IL-10. Eur. Immunol (1999) 29:1275–1285.
   PubMed Web of Science ®Google Scholar
• KWAK B, MULHAUPT F, MYIT S, MACH F: Statins as a newly recognized type of immunomodulator. Nat. Med. (2000) 6:1399–1402.
   PubMed Web of Science ®Google Scholar
• •The first demonstration of the downregulatory effects of various statins on the MHC II transactivator.
   Google Scholar
• DUSTIN ML, SHAW AS: Costimulation: building an immunological synapse. Science (1999) 283:649–650.
   PubMed Web of Science ®Google Scholar
• GRAKOUI A, BROMLEY SK, SUMEN C et al.: The immunological synapse: a molecular machine controlling T cell activation. Science (1999) 285:221–227.
   PubMed Web of Science ®Google Scholar
• SPRINGER TA: Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell (1994) 76:301–314.
   PubMed Web of Science ®Google Scholar
• SPRINGER TA: Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Anna. Rev Physiol (1995) 57:827–872.
   PubMed Web of Science ®Google Scholar
• BAJETTO A, BONAVIA R, BARBERO S, SCHETTINI G: Characterization of chemokines and their receptors in the central nervous system: physiopathological implications. Neurochem. (2002) 82:1311–1329.
   PubMed Web of Science ®Google Scholar
• OLSON TS, LEY K: Chemokines and chemokine receptors in leukocyte trafficking. Am. J. Physiol Regal Integr. Comput. Physiol (2002) 283:R7–R28.
   Google Scholar
• REZAIE P, TRILLO-PAZOS G, EVERALL IP, MALE DK: Expression of P-chemokines and chemokine receptors in human fetal astrocyte and microglial co-cultures: potential role of chemokines in the developing CNS. Glia (2002) 37:64–75.
   PubMedGoogle Scholar
• COLUMBA-CABEZAS S, SERAFINI B, AMBROSINI E et al.: Induction of macrophage-derived chemokine/CCL22 expression in experimental autoimmune encephalomyelitis and cultured microglia: implications for disease regulation. Neuroimmunol (2002) 130:10–21.
   PubMed Web of Science ®Google Scholar
• AMBROSINI E, COLUMBA-CABEZAS S, SERAFINI B, MUSCELLA A, ALOISI F: Astrocytes are the major intracerebral source of macrophage inflammatory protein-3a/CCL20 in relapsing experimental autoimmune encephalomyelitis and M vitro. Glia (2003) 41:290–300.
   PubMed Web of Science ®Google Scholar
• KENNEDY KJ, STRIETER RM, KUNKEL SL, LUKACS NW, KARPUS WJ: Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-la and monocyte chemotactic protein-1. Neuroimmunol (1998) 92:98–108.
   PubMed Web of Science ®Google Scholar
• ROMANO M, DIOMEDE L, SIRONI M et al.: Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab. Invest. (2000) 80:1095–1100.
   PubMed Web of Science ®Google Scholar
• SPRINGER TA, ANDERSON DC: The importance of the Mac-1, LFA-1 glycoprotein family in monocyte and granulocyte adherence, chemotaxis, and migration into inflammatory sites: insights from an experiment of nature. Ciba Found. Symp. (1986) 118:102–126.
   PubMedGoogle Scholar
• WAWRYK SO, NOVOTNY JR, WICKS IPet al.: The role of the LFA-1/ICAM-1 interaction in human leukocyte homing and adhesion. Immunol Rev (1989) 108:135–161.
   Google Scholar
• LEE SJ, BENVENISTE EN: Adhesion molecule expression and regulation on cells of the central nervous system. NeuroimmunoL (1999) 98:77–88.
   PubMed Web of Science ®Google Scholar
• SOBEL RA, MITCHELL ME, FONDREN G: Intercellular adhesion molecule-1 (ICAM-1) in cellular immune reactions in the human central nervous system. Am. J. Athol (1990) 136:1309–1316.
   PubMed Web of Science ®Google Scholar
• WASHINGTON R, BURTON J, TODD RF et al.: Expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microvessels from patients with multiple sclerosis. Ann. Neurol (1994) 35:89–97.
   PubMed Web of Science ®Google Scholar
• BROSNAN CF, CANNELLA B, BATTISTINI L, RAINE CS: Cone localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. Neurology(1995) 45:S16–S21.
   Google Scholar
• CANNELLA B, RAINE CS: The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann. Neurol (1995) 37:424–435.
   PubMed Web of Science ®Google Scholar
• BO L, PETERSON JW, MORK S et al: Distribution of immunoglobulin superfamily members ICAM-1, -2, -3, and the 12 integrin LFA-1 in multiple sclerosis lesions.' Neuropathol Exp. Neurol (1996) 55:1060–1072.
   PubMed Web of Science ®Google Scholar
• FROHMAN EM, FROHMAN TC, DUSTIN ML et al.: The induction of intercellular adhesion molecule 1 (ICAM-1) expression on human fetal astrocytes by interferon-y, tumor necrosis factor a, lymphotwdn, and interleukin-1: relevance to intracerebral antigen presentation. .1. Neuroimmunol (1989) 23:117–124.
   Google Scholar
• MOINGEON P, CHANG HC, WALLNER BP, STEBBINS C, FREY AZ, REINHERZ EL: CD2-mediated adhesion facilitates T lymphocyte antigen recognition function. Nature (1989) 339:312–314.
   PubMedGoogle Scholar
• KALLEN J, WELZENBACH K, RAMAGE P et al.: Structural basis for LFA-1 inhibition upon lovastatin binding to the CD1 la I-domain. J. Ma Biol. (1999) 292:1–9.
   Google Scholar
• YONG VW, POWER C, FORSYTH P, EDWARDS DR: Metalloproteinases in biology and pathology of the nervous system. Nat. Rev Neurosci (2001) 2:502–511.
   PubMed Web of Science ®Google Scholar
• HOWARD L, GLYNN P: Membrane-associated metalloproteinase recognized by characteristic cleavage of myelin basic protein: assay and isolation. Methods Enzymol (1995) 248:388–395.
   PubMedGoogle Scholar
• BELL OSTA S, VIA D, CANAVESI M et al.: HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arteriosclec Thromb. Vase. Biol. (1998) 18:1671–1678.
   PubMedGoogle Scholar
• GANNE F, VASSE M, BEAUDEUX JL et al.: Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes - a possible protective mechanism against atherothrombosis. Thromb. Haemost. (2000) 84:680–688.
   PubMedGoogle Scholar
• ABBAS AK, MURPHY KM, SHER A: Functional diversity of helper T lymphocytes. Nature (1996) 383:787–793.
   PubMed Web of Science ®Google Scholar
• WINDHAGEN A, NICHOLSON LB, WEINER HL, KUCHROO VK, HAFLER DA: Role of TH1 and TH2 cells in neurologic disorders. Chem. Immunol (1996) 63:171–186.
   PubMedGoogle Scholar
• KHOURY SJ, HANCOCK WW, WEINER HL: Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor 13, interleukin 4, and prostaglandin E expression in the brain. .1 Exp. Med. (1992) 176:1355–1364.
   PubMed Web of Science ®Google Scholar
• BEGOLKA WS, VANDERLUGT CL, RAHBE SM, MILLER SD: Differential expression of inflammatory cytokines parallels progression of central nervous system pathology in two clinically distinct models of multiple sclerosis. Immunol (1998) 161:4437–4446.
   Google Scholar
• PANITCH HS, HIRSCH RL, HALEY AS, JOHNSON KP: Exacerbations of multiple sclerosis in patients treated with y interferon. Lancet (1987) 1:893–895.
   PubMed Web of Science ®Google Scholar
• LIU JS, ZHAO ML, BROSNAN CE LEE SC: Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am. Pathol (2001) 158:2057–2066.
   PubMed Web of Science ®Google Scholar
• KAWAHARA K, GOTOH T, OYADOMARI S et al.: Co-induction of argininosuccinate synthetase, cationic amino acid transporter-2, and nitric oxide synthase in activated murine microglial cells. Brain Res. Ma Brain Res. (2001) 90:165–173.
   PubMedGoogle Scholar
• NOMURA Y: NF-icB activation and IicBa dynamism involved in iNOS and chemokine induction in astroglial cells. Life Sci. (2001) 68:1695–1701.
   PubMedGoogle Scholar
• NEUHAUS O, STRASSER-FUCHS S, FAZEKAS F et al.: Statins as immunomodulators: comparison with interferon-I3 lb in MS. Neurology (2002) 59:990–997.
   PubMed Web of Science ®Google Scholar
• VOLLMER T, DURKALSKI V, TYOR W et al: An open-label, single arm study of simvastatin as a therapy for multiple sclerosis (MS). American Academy of Neurology 55th Annual Meeting ProgramS11. (2003) 004. Abstract.
   Google Scholar
• •A small open-label trial that tested the efficacy of simvastatin on patients with clinically defmite RRMS. Analysis of pre- and post-treatment MRI data revealed a reduction of - 45% in the mean number and volume of Gd-enhancing MRI lesions during the treatment period.
   Google Scholar
• DUDA PW, SCHMIED MC, COOK SL, KRIEGER JI, HAFLER DA: Glatiramer acetate (Copaxone) induces degenerate, TH2-polarized immune responses in patients with multiple sclerosis. Clin. Invest. (2000) 105:967–976.
   Google Scholar
• STUVE O, DOOLEY NP, UHM JH et al: Interferon 13-lb decreases the migration of T lymphocytes M vitro: effects on matrix metalloproteinase-9. Ann. Neurol (1996) 40:853–863.
   PubMed Web of Science ®Google Scholar
• LEPPERT D, WAUBANT E, BURK MR, OKSENBERG JR, HAUSER SL: Interferon 13-lb inhibits gelatinase secretion and M vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann. Neurol (1996) 40:846–852.
   PubMed Web of Science ®Google Scholar
• STUVE O, CHABOT S, JUNG SS, WILLIAMS G, YONG VW: Chemokine-enhanced migration of human peripheral blood mononuclear cells is antagonized by interferon I3-lb through an effect on matrix metalloproteinase-9. Neuroimmunol (1997) 80:38–46.
   PubMed Web of Science ®Google Scholar